MEDP vs. CRL, INCY, LH, EXEL, NRC, PGEN, LUNA, ICLR, IQV, and SWAV
Should you be buying Medpace stock or one of its competitors? The main competitors of Medpace include Charles River Laboratories International (CRL), Incyte (INCY), Laboratory Co. of America (LH), Exelixis (EXEL), National Research (NRC), Precigen (PGEN), Luna Innovations (LUNA), ICON Public (ICLR), IQVIA (IQV), and Shockwave Medical (SWAV).
Medpace (NASDAQ:MEDP) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, community ranking, institutional ownership, media sentiment and risk.
In the previous week, Medpace had 3 more articles in the media than Charles River Laboratories International. MarketBeat recorded 22 mentions for Medpace and 19 mentions for Charles River Laboratories International. Medpace's average media sentiment score of 1.02 beat Charles River Laboratories International's score of 0.67 indicating that Medpace is being referred to more favorably in the media.
Medpace has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500.
Charles River Laboratories International has higher revenue and earnings than Medpace. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
Medpace has a net margin of 15.92% compared to Charles River Laboratories International's net margin of 10.81%. Medpace's return on equity of 59.74% beat Charles River Laboratories International's return on equity.
Medpace currently has a consensus price target of $443.00, suggesting a potential upside of 12.64%. Charles River Laboratories International has a consensus price target of $255.27, suggesting a potential upside of 15.19%. Given Charles River Laboratories International's higher possible upside, analysts clearly believe Charles River Laboratories International is more favorable than Medpace.
Charles River Laboratories International received 145 more outperform votes than Medpace when rated by MarketBeat users. However, 64.00% of users gave Medpace an outperform vote while only 61.59% of users gave Charles River Laboratories International an outperform vote.
78.0% of Medpace shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 20.3% of Medpace shares are owned by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Medpace beats Charles River Laboratories International on 11 of the 18 factors compared between the two stocks.
Get Medpace News Delivered to You Automatically
Sign up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MEDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
